Related Experiment Video

Updated: Apr 24, 2026

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

5.5K

Disrupting the KRAS-SOS1 protein-protein interaction: mechanistic rationale for pan-KRAS pathway suppression and

Emadeldin M Kamel1, Sally Mostafa Khadrawy2, Mohamed A M Ali2

  • 1Chemistry Department, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt.

Frontiers in Chemistry
|April 23, 2026
PubMed

Insights

Targeting SOS1 offers a new strategy to control KRAS-driven cancers by blocking RAS-GTP formation. SOS1 inhibitors show promise in combination therapies, potentially overcoming resistance and improving patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Oncogenic KRAS signaling drives many human cancers, but effective pathway suppression is challenging.
  • Existing therapies face limitations including incomplete target coverage and adaptive resistance.
  • Receptor tyrosine kinase (RTK) feedback loops often cause rebound signaling after targeted inhibition.

Purpose of the Study:

  • To review the structural and mechanistic basis of RAS-SOS engagement.
  • To discuss the development and pharmacology of SOS1 inhibitors.
  • To explore the potential of SOS1 inhibitors in combination therapies for cancer treatment.

Main Methods:

  • Review of structural and mechanistic studies on RAS-SOS interactions.
  • Synthesis of pharmacological data from tool compounds and clinical candidates.
  • Analysis of biomarker-linked pharmacodynamic readouts and validation strategies.

Main Results:

  • SOS1 has emerged as a druggable upstream node to modulate KRAS signaling.
  • Small-molecule SOS1 inhibitors disrupt KRAS-SOS1 protein-protein interactions, reducing RAS-GTP formation.
  • SOS1 inhibitors demonstrate potential as 'multiplier' drugs in combination therapies, particularly with MEK and KRAS (G12C) inhibitors.

Conclusions:

  • Targeting SOS1 offers a promising strategy to suppress oncogenic KRAS signaling and overcome resistance mechanisms.
  • Combination strategies involving SOS1 inhibitors are crucial for durable patient benefit.
  • Future directions include developing next-generation inhibitors and degraders for improved efficacy and broader application.
Keywords:
KRASSOS1cancerprotein-protein interactionsmall molecules

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.2K
Protein Extract Preparation and Co-immunoprecipitation from Caenorhabditis elegans07:22

Protein Extract Preparation and Co-immunoprecipitation from Caenorhabditis elegans

Published on: May 23, 2020

10.3K

Related Concept Videos

Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.8K
Protein-protein Interfaces02:04

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.1K
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
7.7K